PRO.MED.CS holding #47 place in the IQVIA pharmaceutical rating, has a small portfolio and an insignificant market share. The main challenges were:
Ursosan grew its sales by 345% (+34% growth each year) IQVIA 2012 – MAT8 2021, RUB
Rebagit, launched in 2016, grew its sales by + 3820% (+636% growth each year) IQVIA 2016 – MAT8 2021, RUB
In 2023 PRO.MED.CS holds #10 place in the IQVIA pharmaceutical rating
Project: 3D popular scientific medical video
Brand: Rebagit (Europe and CIS)
Production: Arkitek Scientific (California, USA)
Copyright © 2024 GrowPro - All Rights Reserved.